SAN DIEGO, June 11, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina’s Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior Vice President and General Counsel, … Read more
SAN DIEGO, June 5, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report, highlighting the company’s commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022. Today, Illumina announced its annual … Read more
Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina’s Board Scott B. Ullem, CFO of Edwards Lifesciences, also named to Board SAN DIEGO, June 2, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes consistent with the goal of enhancing long-term … Read more
Data also shows that current standard-of-care testing for cancer patients falls short in multiple ways SAN DIEGO, May 30, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP) for oncology patients, which will … Read more
SAN DIEGO, May 12, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Institutional Shareholder Services (“ISS”), a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein. Illumina’s Annual Meeting is scheduled … Read more